- 全部删除
- 您的购物车当前为空
Metipranolol (Betamann) 是一种β-肾上腺素能受体(β-adrenergic receptor)的强效拮抗剂,对豚鼠心房β1-肾上腺素受体及大鼠子宫的β2-肾上腺素受体展示出乙型阻断效能(the beta-blocking potencies,pA2)分别为8.3和8.4,它也是3H-DHA结合试验中的强效置换剂,配体浓度0.7 nM时,Ki为39±24 nM。
Metipranolol (Betamann) 是一种β-肾上腺素能受体(β-adrenergic receptor)的强效拮抗剂,对豚鼠心房β1-肾上腺素受体及大鼠子宫的β2-肾上腺素受体展示出乙型阻断效能(the beta-blocking potencies,pA2)分别为8.3和8.4,它也是3H-DHA结合试验中的强效置换剂,配体浓度0.7 nM时,Ki为39±24 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 297 | In stock | |
5 mg | ¥ 483 | In stock | |
10 mg | ¥ 828 | In stock | |
25 mg | ¥ 1,830 | In stock | |
50 mg | ¥ 3,160 | In stock | |
100 mg | ¥ 4,660 | In stock | |
1 mL x 10 mM (in DMSO) | ¥ 636 | In stock |
Metipranolol 相关产品
产品描述 | Metipranolol (Betamann) is a type of β- Adrenergic receptors( β- A potent antagonist of adrenergic receptor on guinea pig atria β 1- Adrenergic receptors and rat uterus β The 2-adrenergic receptor exhibited the beta blocking potentials (pA2) of 8.3 and 8.4, respectively. It is also a potent substituent in the 3H DHA binding assay, with a ligand concentration of 0.7 nM and a Ki of 39 ± 24 nM. |
靶点活性 | β2-adrenoceptor:8.4 (pA2), β1-adrenoceptor:8.3 (pA2) |
体内活性 | Metipranolol applied as eye drops promoted cone photoreceptor function in retinas of rd10 mice greater than subcutaneously injected metipranolol.?The reduced nitrosative damage and rescue of functional loss of photoreceptors in rd10 mice suggests that metipranolol, a drug with established ocular safety and tolerability, may have potential for treating patients with retinitis pigmentosa[1]. |
别名 | 美替洛尔 |
分子量 | 309.4 |
分子式 | C17H27NO4 |
CAS No. | 22664-55-7 |
Smiles | CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C |
密度 | 1.068g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (80.8 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容